Form 4: Mineralys Therapeutics Director Glenn Sblendorio Acquires Stock Options
SEC Form 4 Filing
Director Glenn Sblendorio of Mineralys Therapeutics, Inc. [MLYS] acquired stock options on February 13, 2025.
Summary
- Glenn Sblendorio, a director of Mineralys Therapeutics, Inc., filed a Form 4 on February 24, 2025, reporting a transaction.
- On February 13, 2025, Sblendorio acquired 32,900 stock options with an exercise price of $10.20.
- These options vest in 12 substantially equal monthly installments following the grant date and expire on February 13, 2035.
- Following the reported transaction, Sblendorio directly owns 32,900 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral.
Industry Context
Form 4 filings are standard practice for reporting insider transactions and are a regular part of financial market operations.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of earliest transaction: Glenn Sblendorio acquired stock options. |
| 02/13/2035 | Expiration date of the acquired stock options. |
| 02/24/2025 | Date Form 4 was signed. |
Keywords
Form 4, Mineralys Therapeutics, Stock Options, Director, Sblendorio, MLYS, Acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.